Hostname: page-component-77c89778f8-gvh9x Total loading time: 0 Render date: 2024-07-23T09:07:42.253Z Has data issue: false hasContentIssue false
  • English
  • Français

Effectiveness and quality of life improvement in young adult schizophrenia patients treated with Abilify Maintena

Published online by Cambridge University Press:  19 July 2023

D. Petrić ,
A. Kašelan ,
S. Brozan ,
M. Žuljan Cvitanović  and
D. Krnić
D. Petrić*
Affiliation:
Department of Child and Adolescent Psychiatry, Clinical Hospital Centre Rijeka, Rijeka
A. Kašelan
Affiliation:
Department of Child and Adolescent Psychiatry, Clinical Hospital Centre Rijeka, Rijeka
S. Brozan
Affiliation:
Department of Child and Adolescent Psychiatry, Clinical Hospital Centre Rijeka, Rijeka
M. Žuljan Cvitanović
Affiliation:
Department of psychiatry, University Hospital Centre, Split, Croatia
D. Krnić
Affiliation:
Department of psychiatry, University Hospital Centre, Split, Croatia
*
*Corresponding author.

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

Treating young patients with schizophrenia is a challenge, as these patients have much to gain from controlled pharmacotherapy and even more to lose with a possible relapse. Treating patients with long-acting injectable antipsychotics avoids the issue of non-compliance, the biggest risk factor for relapse, while also improving the quality of life. Receiving a drug once-a-month can provide greater flexibility and convenience to our patients.

Objectives

Aim of the paper is to assess the efficacy and quality of life in monthly dosing of long-acting injectable antipsychotic in young adult schizophrenia patients.

Methods

The research included 7 patients aged 19 to 25 years who were diagnosed in accordance with the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition. Patients were assessed eight times over two years using the following clinical scales: Positive and Negative Syndrome Scale, Clinical Global Impression – Severity and Improvement Scale, Treatment Satisfaction Questionnaire for Medication (TSQM-9) and Quality of Life Scale (QOLS).

Results

All treated patients achieved remission. There was a statistically significant improvement in measured scales in all patients. There were no side-effects reported during the study period, with no relapse or new hospitalizations

Conclusions

The monthly formulation of aripiprazole has proven to be effective and safe in our study and has great potential to improve patient quality of life as well.

Disclosure of Interest

None Declared

Type
Abstract
Information
European Psychiatry , Volume 66 , Special Issue S1: Abstracts of the 31st European Congress of Psychiatry , March 2023 , pp. S1050
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
© The Author(s), 2023. Published by Cambridge University Press on behalf of the European Psychiatric Association
Submit a response

Comments

No Comments have been published for this article.